How patients with neuromyelitis optica spectrum disease accumulate disability
Open Access
- 8 October 2026
- journal article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (13) , 1421-1430
Abstract
Background: It is believed that patients with neuromyelitis optica spectrum disease acquire disability exclusively through relapses. However, the possibility of disability accumulation in the absence of relapses has also been suggested. We quantified irreversible disability accumulation in the presence and absence of relapses in neuromyelitis optica spectrum disease. Methods: We identified patients with neuromyelitis optica spectrum disease in the MSBase registry. Disability-worsening events were required to be sustained until the end of follow-up. Worsening in the absence of relapses was validated through primary record review. Results: Over 884 patient-years of follow-up, we identified 32 disability-worsening events in 31 patients. Notably, six events (18.7%) in five patients (1.9%) occurred in the absence of relapses. A positive association was identified between relapse trajectory and the hazard of disability worsening (hazard ratio (95% credible interval): 2.36 (1.61, 3.64)), and an inverse relationship with disability worsening occurring in the absence of relapses (0.41 (0.11, 1.47)). Conclusion: Irreversible disability worsening was rare in this proactively treated cohort of neuromyelitis optica spectrum disease patients (3.6 events per 100 patient-years). However, almost 19% of worsening occurred in the absence of relapses, reassuringly in only 2% of patients. Our findings support relapses as the principal driver of disability in neuromyelitis optica spectrum disease while also providing evidence of relapse-independent disability worsening beyond identifiable comorbidities.Keywords
Funding Information
- MSBase Foundation (Postdoctoral Fellowship 2022)
- National Health and Medical Research Council (1129189 and 2026836)
This publication has 17 references indexed in Scilit:
- Impact of comorbidities on relapsing rates of Neuromyelitis Optica Spectrum Disorders: Insights from a longitudinal study in TaiwanMultiple Sclerosis and Related Disorders, 2024
- Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGADAnnals of Neurology, 2024
- Progression independent of relapses in aquaporin4-IgG-seropositive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosisMultiple Sclerosis and Related Disorders, 2023
- Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorderJournal of Neurology, Neurosurgery & Psychiatry, 2021
- Optic Neuritis–Independent Retinal Atrophy in Neuromyelitis Optica Spectrum DisorderJournal of Neuro-Ophthalmology, 2021
- Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder BiomarkerAnnals of Neurology, 2021
- Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disordersBrain, 2019
- Retinal ganglion cell loss in neuromyelitis optica: a longitudinal studyJournal of Neurology, Neurosurgery & Psychiatry, 2018
- Subclinical primary retinal pathology in neuromyelitis optica spectrum disorderJournal of Neurology, 2016
- The Pathology of an Autoimmune Astrocytopathy: Lessons Learned from Neuromyelitis OpticaBrain Pathology, 2013